picankibart vs QL2106
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
picankibart
Marketed by Innovent Biologics
NCT05645627 · Phase 3 · completed
CLEAR-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 500 Chinese adults with moderate to severe plaque psoriasis. Patients received picankibart 200 mg or placebo for the first 16 weeks. The two primary endpoints at week 16 were at least 90% improvement in PASI and a clear or almost clear sPGA score. With picankibart, 80.3% reached PASI 90 and 93.5% reached sPGA 0/1, against 2.0% and 13.1% with placebo (p<0.0001 for both), so the trial met both primary endpoints. The response rates come from the peer-reviewed paper in the Journal of the American Academy of Dermatology and the p-values from the company announcement.
Reported efficacy
Percentage of participants with a Psoriasis Area and Severity Index (PASI) 90 Response (Week 56): PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons (met)
Result source: NCT06049810
QL2106
Developed by Qilu Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07511647 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | picankibart | QL2106 |
|---|---|---|
| PASI 75 | —Not posted · NCT05645627 | —Trial running · NCT07511647 |
| PASI 90 | 80.3% vs 2%a+78.3 vs placeboNCT05645627 | —Trial running · NCT07511647 |
| PASI 100 | —Not posted · NCT05645627 | —Trial running · NCT07511647 |
| sPGA 0/1 | —Not posted · NCT05645627 | —Trial running · NCT07511647 |
| DLQI, change | —Not posted · NCT05645627 | —Trial running · NCT07511647 |
PASI 75
- picankibart
- —Not posted · NCT05645627
- QL2106
- —Trial running · NCT07511647
PASI 90
- picankibart
- 80.3% vs 2%a+78.3 vs placeboNCT05645627
- QL2106
- —Trial running · NCT07511647
PASI 100
- picankibart
- —Not posted · NCT05645627
- QL2106
- —Trial running · NCT07511647
sPGA 0/1
- picankibart
- —Not posted · NCT05645627
- QL2106
- —Trial running · NCT07511647
DLQI, change
- picankibart
- —Not posted · NCT05645627
- QL2106
- —Trial running · NCT07511647
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
QL2106: no structured comparison results are available for Psoriasis.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
picankibart
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: picankibart's landscape · QL2106's landscape